Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Palbociclib
Related studies linked through entity extraction aliases.
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.
- Status
- COMPLETED
- Phase
- N/A
ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Swedish Ibrance Registries Insights (SIRI)
- Status
- RECRUITING
- Phase
- N/A
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE2
Umbrella Biomarker-Guided Therapy in NPC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases
- Status
- WITHDRAWN
- Phase
- PHASE1
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
- Status
- RECRUITING
- Phase
- PHASE2
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China
- Status
- UNKNOWN
- Phase
- N/A
Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy
- Status
- COMPLETED
- Phase
- N/A
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE3
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Palbociclib and INCMGA00012 in People With Advanced Liposarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)
- Status
- COMPLETED
- Phase
- PHASE2
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy
- Status
- UNKNOWN
- Phase
- PHASE2